Payment overview · 2025
General Payments
$243.50
8 reported records · 6 companies
Healthcare provider profile · identity verified
Malcolm Symes
Allopathic & Osteopathic Physicians|Family Medicine · MOORESVILLE, NC · NPI 1477040277
Verified facts
What the public records show
CMS Open Payments records show Malcolm Symes received $243.50 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 57.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.65 | 57.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.00 | 14.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.92 | 7.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.28 | 7.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.71 | 6.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.94 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.50 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $140.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 289 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 65 |
| Gabapentin | Gabapentin | 180 | 41 |
| Lisinopril | Lisinopril | 172 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 110 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 32 |
| Omeprazole | Omeprazole | 104 | 28 |
| Losartan Potassium | Losartan Potassium | 102 | 30 |
| Potassium Chloride | Potassium Chloride | 101 | 23 |
| Trazodone Hcl | Trazodone Hcl | 96 | 24 |
| Meloxicam | Meloxicam | 90 | 29 |
| Metformin Hcl | Metformin Hcl | 89 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 24 |
| Furosemide | Furosemide | 81 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 23 |
| Metformin Hcl Er | Metformin Hcl | 71 | 21 |
| Ozempic | Semaglutide | 71 | 12 |
| Buspirone Hcl | Buspirone Hcl | 70 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 23 |
| Ibuprofen | Ibuprofen | 66 | 23 |
| Carvedilol | Carvedilol | 63 | 13 |
| Promethazine Hcl | Promethazine Hcl | 60 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 17 |
| Allopurinol | Allopurinol | 52 | 13 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 23 |
| Simvastatin | Simvastatin | 49 | 14 |
| Prednisone | Prednisone | 48 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 11 |
| Jardiance | Empagliflozin | 46 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 12 |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Pregabalin | Pregabalin | 41 | 11 |
| Famotidine | Famotidine | 40 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 11 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 11 |
| Azithromycin | Azithromycin | 34 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 18 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.50 · 8 records | PFIZER INC. | FARXIGA, NURTEC ODT, Ozempic, Rybelsus, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error